European Journal of Clinical Pharmacology

, Volume 43, Issue 5, pp 559–562 | Cite as

Pharmacokinetics of famotidine in patients with cirrhosis and ascites

  • G. Vinçon
  • C. Baldit
  • P. Couzigou
  • F. Demotes-Mainard
  • L. Elouaer-Blanca
  • B. Bannwarth
  • B. Begaud
Short Communications


The pharmacokinetics of famotidine has been investigated in ascitic cirrhotic patients. 10 decompensated cirrhotic patients were studied (9 m, 1 f), who had normal renal function, and six healthy control subjects (4 m, 2 f), matched for age, sex and weight. Each subject received on two occasions, at least four days apart, a single oral (40 mg) or intravenous dose (20 mg) of famotidine, at 21.00 h in a randomised manner. Serial blood samples were collected and famotidine in plasma was determined by a HPLC/UV method. Plasma data were subjected to non compartmental pharmacokinetic analysis.

There were no statistically significant differences in pharmacokinetic parameters between the two groups after either the intravenous or oral administration of famotidine.

The findings suggest that the dose of famotidine may not require any adjustment in ascitic patients without renal failure.

Key words

Famotidine, Cirrhosis pharmacokinetics, ascites 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burroughs AK, Blake J, Kochlar S, Thorne S, Else M, Rolles K (1990) Prospective study of comparative costs of liver transplantation and the treatment of complications in cirrhotic patients. Gut 31: 1627Google Scholar
  2. 2.
    Albin H, Couzigou P, Vinçon G, Péhourcq F, Fleury B, Béraud C (1983) Pharmacocinétique de la cimétidine chez le cirrhotique ascitique. Gastroentérol Clin Biol 7: 251–255Google Scholar
  3. 3.
    Bretagne JF, Reymann JM, Tassou JJ, Allain H, Gosselin A, Gastard J (1983) Pharmacocinétique de la ranitidine par voie intraveineuse et son effet sur la sécrétion gastrique acide stimulée par la pentagastrine chez le cirrhotique. Gastroentérol Clin Biol 7: 355–361Google Scholar
  4. 4.
    Ohnishi K (1991) Pharmacokinetics of famotidine after intravenous administration in liver disease. Am J Gastroenterol 86: 41–45Google Scholar
  5. 5.
    Morgan MY, Stambuk D (1986) Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study. Postgrad Med J 62 [Suppl 2]: 29–37Google Scholar
  6. 6.
    Morgan MY, Stambuk D, Cottrell J, Mann SG (1990) Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. Aliment Pharmacol Ther 4: 83–96Google Scholar
  7. 7.
    Pugh RNH, Murray-Iyon IM, Dawson JL, Pietroni NC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646–649Google Scholar
  8. 8.
    Vincek WC, Constanzer MC, Hessey GA, Bayne WF (1985) Analytical method for the quantification of famotidine, an H2-receptor blocker in plasma and urine. J Chromatogr 338: 438–443Google Scholar
  9. 9.
    Benet LZ, Galeazzi RL (1979) Non compartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074Google Scholar
  10. 10.
    Damann HG, Muller P, Simon B (1983) Twenty four hours intragastric acidity and single night-time dose of three H2-blockkes. Lancet 2: 1078Google Scholar
  11. 11.
    Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J (1987) Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol 24: 551–553Google Scholar
  12. 12.
    Kroemer H, Klotz U (1987) Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol 25: 458–463Google Scholar
  13. 13.
    Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, Hattori N (1985) Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol 28: 327–331Google Scholar
  14. 14.
    Langtry HD, Grant SM, Goa KL (1989) Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 38: 551–590Google Scholar
  15. 15.
    Inotsume N, Nishimura M, Fujiyama S, Sagara K, Sato T, Imai Y, Matsui H, Nakano M (1989) Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. Eur J Clin Pharmacol 36: 517–520Google Scholar
  16. 16.
    Halstenson CE, Abraham PA, Opsahl JA, Keane WF, Kovarik JM, Chremos AN, Matzke GR (1986) Disposition of famotidine in renal insufficiency. Clin Pharmacol Ther 39: 197Google Scholar
  17. 17.
    Hucker HB, Hutt JE, Chremos AN, Rotmensch H (1984) Disposition and metabolism of famotidine, a potent H2-receptor blocker, in man. Fed Proc 43: 655Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • G. Vinçon
    • 1
  • C. Baldit
    • 2
  • P. Couzigou
    • 2
  • F. Demotes-Mainard
    • 1
  • L. Elouaer-Blanca
    • 3
  • B. Bannwarth
    • 1
  • B. Begaud
    • 1
  1. 1.Service de Pharmacologie CliniqueHôpital Pellegrin & Université de Bordeaux 11-CarreireBordeaux CedexFrance
  2. 2.Service de GastroentérologieHôpital du Haut-LévêquePessacFrance
  3. 3.Laboratoires Merck Sharp & Dohme-ChibretParisFrance

Personalised recommendations